TB-500 is explicitly listed on the WADA prohibited substances list (BPC-157 is not explicitly listed)
However, semaglutide oral tablets are not approved for the reduction of CV events.As with other agents in this class, semaglutide has a boxed warning regarding rodent thyroid C-cell tumor findings and the uncertain relevance to humans.First-line T2DM therapy depends on comorbidities, patient-centered treatment factors, and management needs and generally includes metformin and comprehensive lifestyle modification
Remove any unsupported claims, language about treating disease, "FDA-approved" tags that aren't accurate, and vague peptide menus
However, based on the research to date, researchers will want to consider the following guidelines when when administering these peptides: Subcutaneous and intramuscular injections are considered more effective due to enhanced bioavailability , but using BPC-157 + TB-500 nasal spray could have certain advantages depending on the therapeutic objective and study design
Inflammation and tissue regeneration